CSIMarket
 
Aprea Therapeutics Inc   (APRE)
Other Ticker:  
 
 
Price: $6.5500 $0.36 5.816%
Day's High: $6.79 Week Perf: 6.33 %
Day's Low: $ 5.79 30 Day Perf: 14.93 %
Volume (M): 28 52 Wk High: $ 8.85
Volume (M$): $ 185 52 Wk Avg: $4.36
Open: $6.22 52 Wk Low: $2.78



 Market Capitalization (Millions $) 24
 Shares Outstanding (Millions) 4
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -13
 Cash Flow (TTM) (Millions $) -7
 Capital Exp. (TTM) (Millions $) 0

Aprea Therapeutics Inc
Aprea Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel cancer treatments. The company is primarily engaged in the research and development of small molecule drugs that restore the tumor suppressor protein p53 to its normal function. p53 is a crucial protein involved in regulating cell division and preventing the formation of cancerous tumors.

Aprea Therapeutics' lead candidate is called APR-246, which has shown promising results in clinical trials for various types of cancers, including hematologic malignancies and solid tumors. APR-246 works by reactivating mutated or inactivated p53 to induce apoptosis, or programmed cell death, in cancer cells while sparing healthy cells.

The company also has other research programs focused on addressing different aspects of p53 biology through drug discovery efforts. Aprea Therapeutics aims to develop innovative therapies that can significantly impact the lives of patients with cancer and improve treatment options.

Founded in 2003 and headquartered in Boston, Massachusetts, Aprea Therapeutics has collaborations and partnerships with various academic institutions, as well as pharmaceutical and biotechnology companies. The company's advancements in p53 biology and the development of APR-246 have garnered significant attention in the field of oncology.


   Company Address: 3805 Old Easton Road Doylestown 18902 PA
   Company Phone Number: 463-9385   Stock Exchange / Ticker: NASDAQ APRE
   APRE is expected to report next financial results on March 29, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Financing Agreement

Aprea Therapeutics' Financial Health Shines Amidst Industry Challenges

Published Mon, Mar 11 2024 12:30 PM UTC


(Article Body)
In a recent announcement made by Aprea Therapeutics Inc, the biotechnology company shared news of a private placement financing round that could potentially yield up to $34.0 million. The financing, led by Sphera Healthcare and joined by both new and existing healthcare-focused institutional investors, positions Aprea Therapeutics for continued growth...

Clinical Study

Promising Progress: Aprea Therapeutics Spearheads Precision Oncology with DNA Damage Response Agents

Published Thu, Jan 4 2024 9:05 PM UTC

In the field of oncology, precision medicine has revolutionized the way cancer is diagnosed and treated. One promising area of research is synthetic lethality, which focuses on exploiting weaknesses in cancer cells that are dependent on specific genes or pathways for survival. Aprea Therapeutics, a clinical-stage biopharmaceutical company, is at the forefront of this innovat...

Aprea Therapeutics Inc

Aprea Therapeutics Inc. Reports a Substantial Operating Deficit of $-3.52285 Million for Q3 2023



The third quarter of 2023 has brought positive developments for Aprea Therapeutics Inc, a major player in the Pharmaceutical Preparations industry. With the operating deficit shrinking and revenue streams showing signs of growth, investors are gaining confidence in the company's potential. This article will delve into Aprea Therapeutics Inc's recent financial performance and discuss its impact on the market.
Decreasing Operating Deficit
Aprea Therapeutics Inc recently reported an operating deficit of $-3.52285 million for the third quarter of 2023. This marks a significant improvement from the $-4.200194 million deficit reported during the same period last year. The reduction in the operating deficit showcases the company's commitment to efficiency and cost optimization.

Aprea Therapeutics Inc

Aprea Therapeutics Inc Posts Significantly Reduced Operating Deficit of $-3.651681 Million in Q2 2023 Financial Report, Reflecting Strong Financial Stability and Operational Efficiency


Date: October 1, 2023
As investors closely monitor the major players in the pharmaceutical preparations sector, Aprea Therapeutics Inc has emerged with noteworthy Q2 2023 results, signaling positive changes for the company. Aprea Therapeutics Inc, an emerging growth entity, aims to compete more cost-effectively to achieve further growth and become a leader in the industry.
In the second quarter of 2023, Aprea Therapeutics reported an operating deficit of $-3.651681 million. While this indicates a deficit, it represents a significant improvement compared to the same quarter in 2022, where the operating deficit stood at $-98.465531 million. This substantial reduction demonstrates the company's commitment to financial stability and efficient operations.

Aprea Therapeutics Inc

APRE Reports Negative ROE in Q1 2023, But Shows Positive Trend in Ranking within Personal Services Industry

Aprea Therapeutics Inc has recorded a cumulative net loss of $-109 million during 12 months ending in the first quarter 2023, resulting in a negative return on equity (ROE) of -1015.57%. While this result shows that the company has not been profitable in the past year, it is important to note that evolving entities like APRE are still unfolding their business models, and it is becoming increasingly crucial for them to compete competently to achieve their goals.
Despite this, APRE has reported a positive trend in its return on equity, with the overall ranking advancing from 4360 to 3192 in the quarter. While this is still lower than 20 other companies in the Personal Services industry, it indicates that APRE is moving in the right direction.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com